Drug Trial Radar · NCT03518320
Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
Last checked: Nov 19, 2026Latest source record: Aug 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
13
Actual
Start
Jan 2, 2019
Primary completion
Dec 11, 2019
Study completion Dec 11, 2019
Sponsor
- Lead sponsor
- Taris Biomedical LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- May 8, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if TAR-200, an investigational drug delivery system, in combination with nivolumab is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are scheduled for radical cystectomy (RC) during an 84-day dosing cycle induction period comprised of four consecutive 21-day dosing cycles.
Conditions
- Bladder Cancer TNM Staging Primary Tumor (T) T2
- Bladder Cancer TNM Staging Primary Tumor (T) T2A
- Bladder Cancer TNM Staging Primary Tumor (T) T2B
- Bladder Cancer TNM Staging Primary Tumor (T) T3
- Bladder Cancer TNM Staging Primary Tumor (T) T3A
- Bladder Cancer TNM Staging Primary Tumor (T) T3B
- Bladder Cancer TNM Staging Regional Lymph Node (N) N0
- Bladder Cancer TNM Staging Regional Lymph Node (N) N1
- Bladder Cancer TNM Staging Distant Metastasis (M) M0
Interventions
Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200Drug
TAR-200 will be placed in the bladder through an inserter and gradually release gemcitabine for four consecutive 21-day dosing cycles for a total period of approximately 84 days
Nivolumab Injection [Opdivo]Drug
Nivolumab will be given intravenously on specified days for four consecutive 21-day dosing cycles for a total period of approximately 84 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with incidence of treatment emergent adverse events (TEAEs) over 4 consecutive 21-day dosing cycles of TAR-200 in combination with Nivolumab as assessed by CTCAE V4.0.Time frame: Study Day 0 to Study Day 180
- Number of participants that do not require treatment discontinuation prior to the scheduled end date due to meeting any of the Subject Stopping Safety criteria or other drug or device related AETime frame: Study Day 0 to Study Day 180
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
DuPage Medical Group
Hinsdale, Illinois
University of Rochester Medical Center
Rochester, New York
Duke University Medical Center
Durham, North Carolina
The University of Oklahoma Stephenson Cancer Center
Oklahoma City, Oklahoma
Thomas Jefferson University
Philadelphia, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.